Research ArticleAccepted Article
The Interplay between Covid-19 and Spondyloarthritis or Its Treatment
James T. Rosenbaum, Michael H. Weisman, Hedley Hamilton, Cassie Shafer, Elin Aslanyan, Richard A. Howard, Kimberly Ogle, John D. Reveille, Kevin L. Winthrop and Dongseok Choi
The Journal of Rheumatology October 2021, jrheum.210742; DOI: https://doi.org/10.3899/jrheum.210742
James T. Rosenbaum
Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute 1040 NW 22nd Avenue Portland, OR, USA; Cedars Sinai Medical Center Los Angeles, CA, USA; Any-3 London, United Kingdom; Spondylitis Association of America Los Angeles, CA, USA; Department of Medicine University of Texas, Houston Houston, TX, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology Oregon Health & Science University Portland, OR. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Abbvie played no role in the study design, data interpretation, or writing of the results. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. Conflicts of Interest: JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; he receives royalties from UpToDate; he receives grant support from Pfizer and Horizon. He serves on a data monitoring committee for Celgene-Bristol Myers. HH owns Any3, the website which hosted the survey and donated its services. RAH owns stock in Abbvie, Amgen, Bristol-Myers, Glaxo Smith Kline, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB. He receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead. He receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no potential conflicts. None of the authors believe that the above relationships influenced the contents of this report. Ethics: This study complied with principles in the Declaration of Helsinki. The study was reviewed and approved by the Oregon Health & Science University Institutional Review Board (approval number 21375). Subjects who participated in this research provided electronic consent as a first step in completing the survey. As a survey, it was not practical to obtain written, informed consent. Address correspondence to James T. Rosenbaum,Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd. L467Ad Portland, Oregon, USA 97239
Michael H. Weisman
Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute 1040 NW 22nd Avenue Portland, OR, USA; Cedars Sinai Medical Center Los Angeles, CA, USA; Any-3 London, United Kingdom; Spondylitis Association of America Los Angeles, CA, USA; Department of Medicine University of Texas, Houston Houston, TX, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology Oregon Health & Science University Portland, OR. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Abbvie played no role in the study design, data interpretation, or writing of the results. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. Conflicts of Interest: JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; he receives royalties from UpToDate; he receives grant support from Pfizer and Horizon. He serves on a data monitoring committee for Celgene-Bristol Myers. HH owns Any3, the website which hosted the survey and donated its services. RAH owns stock in Abbvie, Amgen, Bristol-Myers, Glaxo Smith Kline, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB. He receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead. He receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no potential conflicts. None of the authors believe that the above relationships influenced the contents of this report. Ethics: This study complied with principles in the Declaration of Helsinki. The study was reviewed and approved by the Oregon Health & Science University Institutional Review Board (approval number 21375). Subjects who participated in this research provided electronic consent as a first step in completing the survey. As a survey, it was not practical to obtain written, informed consent. Address correspondence to James T. Rosenbaum,Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd. L467Ad Portland, Oregon, USA 97239
Hedley Hamilton
Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute 1040 NW 22nd Avenue Portland, OR, USA; Cedars Sinai Medical Center Los Angeles, CA, USA; Any-3 London, United Kingdom; Spondylitis Association of America Los Angeles, CA, USA; Department of Medicine University of Texas, Houston Houston, TX, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology Oregon Health & Science University Portland, OR. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Abbvie played no role in the study design, data interpretation, or writing of the results. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. Conflicts of Interest: JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; he receives royalties from UpToDate; he receives grant support from Pfizer and Horizon. He serves on a data monitoring committee for Celgene-Bristol Myers. HH owns Any3, the website which hosted the survey and donated its services. RAH owns stock in Abbvie, Amgen, Bristol-Myers, Glaxo Smith Kline, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB. He receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead. He receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no potential conflicts. None of the authors believe that the above relationships influenced the contents of this report. Ethics: This study complied with principles in the Declaration of Helsinki. The study was reviewed and approved by the Oregon Health & Science University Institutional Review Board (approval number 21375). Subjects who participated in this research provided electronic consent as a first step in completing the survey. As a survey, it was not practical to obtain written, informed consent. Address correspondence to James T. Rosenbaum,Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd. L467Ad Portland, Oregon, USA 97239
Cassie Shafer
Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute 1040 NW 22nd Avenue Portland, OR, USA; Cedars Sinai Medical Center Los Angeles, CA, USA; Any-3 London, United Kingdom; Spondylitis Association of America Los Angeles, CA, USA; Department of Medicine University of Texas, Houston Houston, TX, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology Oregon Health & Science University Portland, OR. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Abbvie played no role in the study design, data interpretation, or writing of the results. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. Conflicts of Interest: JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; he receives royalties from UpToDate; he receives grant support from Pfizer and Horizon. He serves on a data monitoring committee for Celgene-Bristol Myers. HH owns Any3, the website which hosted the survey and donated its services. RAH owns stock in Abbvie, Amgen, Bristol-Myers, Glaxo Smith Kline, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB. He receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead. He receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no potential conflicts. None of the authors believe that the above relationships influenced the contents of this report. Ethics: This study complied with principles in the Declaration of Helsinki. The study was reviewed and approved by the Oregon Health & Science University Institutional Review Board (approval number 21375). Subjects who participated in this research provided electronic consent as a first step in completing the survey. As a survey, it was not practical to obtain written, informed consent. Address correspondence to James T. Rosenbaum,Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd. L467Ad Portland, Oregon, USA 97239
Elin Aslanyan
Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute 1040 NW 22nd Avenue Portland, OR, USA; Cedars Sinai Medical Center Los Angeles, CA, USA; Any-3 London, United Kingdom; Spondylitis Association of America Los Angeles, CA, USA; Department of Medicine University of Texas, Houston Houston, TX, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology Oregon Health & Science University Portland, OR. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Abbvie played no role in the study design, data interpretation, or writing of the results. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. Conflicts of Interest: JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; he receives royalties from UpToDate; he receives grant support from Pfizer and Horizon. He serves on a data monitoring committee for Celgene-Bristol Myers. HH owns Any3, the website which hosted the survey and donated its services. RAH owns stock in Abbvie, Amgen, Bristol-Myers, Glaxo Smith Kline, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB. He receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead. He receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no potential conflicts. None of the authors believe that the above relationships influenced the contents of this report. Ethics: This study complied with principles in the Declaration of Helsinki. The study was reviewed and approved by the Oregon Health & Science University Institutional Review Board (approval number 21375). Subjects who participated in this research provided electronic consent as a first step in completing the survey. As a survey, it was not practical to obtain written, informed consent. Address correspondence to James T. Rosenbaum,Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd. L467Ad Portland, Oregon, USA 97239
Richard A. Howard
Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute 1040 NW 22nd Avenue Portland, OR, USA; Cedars Sinai Medical Center Los Angeles, CA, USA; Any-3 London, United Kingdom; Spondylitis Association of America Los Angeles, CA, USA; Department of Medicine University of Texas, Houston Houston, TX, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology Oregon Health & Science University Portland, OR. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Abbvie played no role in the study design, data interpretation, or writing of the results. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. Conflicts of Interest: JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; he receives royalties from UpToDate; he receives grant support from Pfizer and Horizon. He serves on a data monitoring committee for Celgene-Bristol Myers. HH owns Any3, the website which hosted the survey and donated its services. RAH owns stock in Abbvie, Amgen, Bristol-Myers, Glaxo Smith Kline, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB. He receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead. He receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no potential conflicts. None of the authors believe that the above relationships influenced the contents of this report. Ethics: This study complied with principles in the Declaration of Helsinki. The study was reviewed and approved by the Oregon Health & Science University Institutional Review Board (approval number 21375). Subjects who participated in this research provided electronic consent as a first step in completing the survey. As a survey, it was not practical to obtain written, informed consent. Address correspondence to James T. Rosenbaum,Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd. L467Ad Portland, Oregon, USA 97239
Kimberly Ogle
Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute 1040 NW 22nd Avenue Portland, OR, USA; Cedars Sinai Medical Center Los Angeles, CA, USA; Any-3 London, United Kingdom; Spondylitis Association of America Los Angeles, CA, USA; Department of Medicine University of Texas, Houston Houston, TX, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology Oregon Health & Science University Portland, OR. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Abbvie played no role in the study design, data interpretation, or writing of the results. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. Conflicts of Interest: JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; he receives royalties from UpToDate; he receives grant support from Pfizer and Horizon. He serves on a data monitoring committee for Celgene-Bristol Myers. HH owns Any3, the website which hosted the survey and donated its services. RAH owns stock in Abbvie, Amgen, Bristol-Myers, Glaxo Smith Kline, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB. He receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead. He receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no potential conflicts. None of the authors believe that the above relationships influenced the contents of this report. Ethics: This study complied with principles in the Declaration of Helsinki. The study was reviewed and approved by the Oregon Health & Science University Institutional Review Board (approval number 21375). Subjects who participated in this research provided electronic consent as a first step in completing the survey. As a survey, it was not practical to obtain written, informed consent. Address correspondence to James T. Rosenbaum,Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd. L467Ad Portland, Oregon, USA 97239
John D. Reveille
Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute 1040 NW 22nd Avenue Portland, OR, USA; Cedars Sinai Medical Center Los Angeles, CA, USA; Any-3 London, United Kingdom; Spondylitis Association of America Los Angeles, CA, USA; Department of Medicine University of Texas, Houston Houston, TX, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology Oregon Health & Science University Portland, OR. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Abbvie played no role in the study design, data interpretation, or writing of the results. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. Conflicts of Interest: JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; he receives royalties from UpToDate; he receives grant support from Pfizer and Horizon. He serves on a data monitoring committee for Celgene-Bristol Myers. HH owns Any3, the website which hosted the survey and donated its services. RAH owns stock in Abbvie, Amgen, Bristol-Myers, Glaxo Smith Kline, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB. He receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead. He receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no potential conflicts. None of the authors believe that the above relationships influenced the contents of this report. Ethics: This study complied with principles in the Declaration of Helsinki. The study was reviewed and approved by the Oregon Health & Science University Institutional Review Board (approval number 21375). Subjects who participated in this research provided electronic consent as a first step in completing the survey. As a survey, it was not practical to obtain written, informed consent. Address correspondence to James T. Rosenbaum,Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd. L467Ad Portland, Oregon, USA 97239
Kevin L. Winthrop
Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute 1040 NW 22nd Avenue Portland, OR, USA; Cedars Sinai Medical Center Los Angeles, CA, USA; Any-3 London, United Kingdom; Spondylitis Association of America Los Angeles, CA, USA; Department of Medicine University of Texas, Houston Houston, TX, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology Oregon Health & Science University Portland, OR. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Abbvie played no role in the study design, data interpretation, or writing of the results. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. Conflicts of Interest: JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; he receives royalties from UpToDate; he receives grant support from Pfizer and Horizon. He serves on a data monitoring committee for Celgene-Bristol Myers. HH owns Any3, the website which hosted the survey and donated its services. RAH owns stock in Abbvie, Amgen, Bristol-Myers, Glaxo Smith Kline, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB. He receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead. He receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no potential conflicts. None of the authors believe that the above relationships influenced the contents of this report. Ethics: This study complied with principles in the Declaration of Helsinki. The study was reviewed and approved by the Oregon Health & Science University Institutional Review Board (approval number 21375). Subjects who participated in this research provided electronic consent as a first step in completing the survey. As a survey, it was not practical to obtain written, informed consent. Address correspondence to James T. Rosenbaum,Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd. L467Ad Portland, Oregon, USA 97239
Dongseok Choi
Departments of Medicine, Ophthalmology, and Cell Biology Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute 1040 NW 22nd Avenue Portland, OR, USA; Cedars Sinai Medical Center Los Angeles, CA, USA; Any-3 London, United Kingdom; Spondylitis Association of America Los Angeles, CA, USA; Department of Medicine University of Texas, Houston Houston, TX, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology Oregon Health & Science University Portland, OR. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Abbvie played no role in the study design, data interpretation, or writing of the results. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. Conflicts of Interest: JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody, Revolo, Roivant, and Neoleukin; he receives royalties from UpToDate; he receives grant support from Pfizer and Horizon. He serves on a data monitoring committee for Celgene-Bristol Myers. HH owns Any3, the website which hosted the survey and donated its services. RAH owns stock in Abbvie, Amgen, Bristol-Myers, Glaxo Smith Kline, Johnson and Johnson, Lilly, Merck, Novartis, Pfizer, and Teva. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB. He receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead. He receives research support from BMS and Pfizer. CS, EA, and RAH are employed by the Spondylitis Association of America. DC and KO report no potential conflicts. None of the authors believe that the above relationships influenced the contents of this report. Ethics: This study complied with principles in the Declaration of Helsinki. The study was reviewed and approved by the Oregon Health & Science University Institutional Review Board (approval number 21375). Subjects who participated in this research provided electronic consent as a first step in completing the survey. As a survey, it was not practical to obtain written, informed consent. Address correspondence to James T. Rosenbaum,Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd. L467Ad Portland, Oregon, USA 97239
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
The Interplay between Covid-19 and Spondyloarthritis or Its Treatment
James T. Rosenbaum, Michael H. Weisman, Hedley Hamilton, Cassie Shafer, Elin Aslanyan, Richard A. Howard, Kimberly Ogle, John D. Reveille, Kevin L. Winthrop, Dongseok Choi
The Journal of Rheumatology Oct 2021, jrheum.210742; DOI: 10.3899/jrheum.210742
Accepted manuscript
The Interplay between Covid-19 and Spondyloarthritis or Its Treatment
James T. Rosenbaum, Michael H. Weisman, Hedley Hamilton, Cassie Shafer, Elin Aslanyan, Richard A. Howard, Kimberly Ogle, John D. Reveille, Kevin L. Winthrop, Dongseok Choi
The Journal of Rheumatology Oct 2021, jrheum.210742; DOI: 10.3899/jrheum.210742